ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Spins Off A Hearing-Drug Firm

by Lisa M. Jarvis
August 29, 2011 | APPEARED IN VOLUME 89, ISSUE 35

GlaxoSmithKline has taken a minority stake in Autifony Therapeutics, a spin-off of GSK’s early-stage hearing disorder assets. The investment firms Imperial Innovations and SV Life Sciences will each contribute roughly $8 million to the start-up. Autifony will focus on developing modulators of voltage-gated ion channels to treat hearing loss and tinnitus. It hopes to put its first compound into Phase I studies by early 2013.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment